These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 576879)

  • 1. Comparative bioavaiability of four commercial quinidine sulfate tablets.
    Strum JD; Colaizzi JL; Jaffe JM; Martineau PC; Poust RI
    J Pharm Sci; 1977 Apr; 66(4):539-42. PubMed ID: 576879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative bioavailability characteristics of commercial quinidine polygalacturonate and sulfate tablets.
    Dahl JR; Ueda CT; Meyers DG; Wulf BG
    DICP; 1990; 24(7-8):685-8. PubMed ID: 2375136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of quinidine absorption with disintegration and dissolution rates.
    Strum JD; Ebersole JW; Jaffe JM; Colaizzi JL; Poust RI
    J Pharm Sci; 1978 Apr; 67(4):568-9. PubMed ID: 641776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of three commercial sustained-release tablets of quinidine in maintenance therapy.
    Huynh-Ngoc T; Chabot M; Sirois G
    J Pharm Sci; 1978 Oct; 67(10):1456-9. PubMed ID: 702302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal absorption of quinidine from some solutions and commercial tablets.
    Guentert TW; Upton RA; Holford NH; Bostrom A; Riegelman S
    J Pharmacokinet Biopharm; 1980 Jun; 8(3):243-55. PubMed ID: 7420269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of 11 quinidine formulations adn pharmacokinetic variation in humans.
    McGilveray IJ; Midha KK; Rowe M; Beaudoin N; Charette C
    J Pharm Sci; 1981 May; 70(5):524-9. PubMed ID: 7241357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition kinetics of two oral forms of quinidine.
    Mahon WA; Mayersohn M; Inaba T
    Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):566-75. PubMed ID: 1277713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations.
    Frigo GM; Perucca E; Teggia-Droghi M; Gatti G; Mussini A; Salerno J
    Br J Clin Pharmacol; 1977 Aug; 4(4):449-54. PubMed ID: 901736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of two manufacturers' sustained-release quinidine gluconate tablets at steady state.
    Zinny MA; Taggart WV
    Clin Ther; 1984; 7(1):22-7. PubMed ID: 6518461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absolute quinidine bioavailability.
    Ueda CT; Williamson BJ; Dzindzio BS
    Clin Pharmacol Ther; 1976 Sep; 20(3):260-5. PubMed ID: 954347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of a commercial sustained-release quinidine tablet compared to oral quinidine solution.
    Sawyer WT; Pulliam CC; Mattocks A; Foster J; Hadzija BW; Rosenthal HM
    Biopharm Drug Dispos; 1982; 3(4):301-10. PubMed ID: 7159686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate.
    Taggart WV; Holyoak W
    Clin Ther; 1983; 5(4):357-64. PubMed ID: 6871920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability of tolazamide from tablets: comparison of in vitro and in vivo results.
    Welling PG; Patel RB; Patel UR; Gillespie WR; Craig WA; Albert KS
    J Pharm Sci; 1982 Nov; 71(11):1259-63. PubMed ID: 7175719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative bioavailability of quinidine gluconate and quinidine sulfate in healthy volunteers.
    Covinsky JO; Russo J; Kelly KL; Cashman J; Amick EN; Mason WD
    J Clin Pharmacol; 1979; 19(5-6):261-9. PubMed ID: 469022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enteric coated quinidine compared to sustained release preparations during repeated administration.
    Bakke OM; Aanderud L; Aslaksen A
    Acta Med Scand; 1980; 207(3):183-7. PubMed ID: 7368984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of food and an antacid on quinidine bioavailability.
    Ace LN; Jaffe JM; Kunka RL
    Biopharm Drug Dispos; 1983; 4(2):183-90. PubMed ID: 6882885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum quinidine levels after chronic administration of four different quinidine formulations.
    Soeterboek AM; Van Thiel M; Eng C
    J Int Med Res; 1976; 4(6):393-401. PubMed ID: 1027633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative bioavailability of praziquantel tablets.
    Kaojarern S; Nathakarnkikool S; Suvanakoot U
    DICP; 1989 Jan; 23(1):29-32. PubMed ID: 2718480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absorption of quinidine from an enteric-coated preparation.
    Fremstad D; Nilsen OG; Amlie J; Storstein L; Olsson B; Jacobsen S
    Eur J Clin Pharmacol; 1979 Sep; 16(2):107-12. PubMed ID: 499306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.